ReviewFrontiers in physiology2026
From single-pathway cascade to network pathophysiology: how genetically engineered mouse models reshaped our understanding of pancreatitis.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatitis remains a common gastrointestinal disease with no mechanism-specific therapy. Its pathogenesis was long explained by the autodigestion hypothesis: a single linear cascade initiated by premature intra-acinar trypsinogen activation. This trypsin-centric view cannot account for the amplification of inflammation, the switching of cell-death modality, the acute-to-chronic transition, organ failure, or the chronic pancreatitis caused by protein-misfolding genes that act outside the protease system. Here we synthesize evidence from genetically engineered mouse models (GEMMs); their loss- and gain-of-function designs, spanning global and conditional knockouts, knock-ins, and CRISPR/Cas9 editing, can separate molecular events that are necessary, sufficient, or merely correlated. These models show, for example, that enhanced trypsinogen autoactivation alone is sufficient for spontaneous disease, that NF-κB-driven inflammation can be initiated independently of trypsin, and that loss of autophagy alone disrupts acinar homeostasis. On this basis we reframe pancreatitis as a network pathophysiology with two coupled layers. First, acinar homeostasis is maintained by several semi-independent control modules (digestive-enzyme safety, endoplasmic reticulum protein quality control, the autophagy-lysosome system, the calcium-mitochondria axis, and NF-κB signaling), so that disease can be initiated at any of several independent nodes. Second, the injured acinar cell dies through an interconnected, switchable network of regulated cell death (apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis), sharing nodes such as caspase-8, RIPK3, and GPX4, whose configuration, more than the initiating trigger, determines severity. This framework recasts the heterogeneity of human pancreatitis as different entry points into one network and argues for therapies directed at shared nodes rather than single pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.